Bayer AG

Bayer AG: ESG outlook clouded by potential Monsanto liability

October 30, 2018

Sign In to Research

Research briefs are only available to current customers. If you would like to learn more about our Platform and Data products and how we generate unique investment ideas, contact us.

After the merger with Monsanto and the verdict in a legacy lawsuit, Bayer stock is at a multi-year low.

Submit the form to read the research brief and explore:

  • ESG issues that are now woven into Bayer’s fundamental outlook
  • Other potential risks within Bayer‘s agriculture business
Industry
Pharmaceuticals

Material Categories
Customer Welfare
Human Rights and Community Relations
Product Quality and Safety